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Acute myeloid leukemia (AML) is a cancer of the bone marrow that has large outcome variability 
among affected patients. The disease is relatively rare, accounting for only 1.2 % of all cancer 
deaths in the United States, but is expected to increase in incidence. A number of factors have been 
identified to facilitate diagnostic classification and risk assessment, but when it comes to predicting 
individual outcomes much less is known. The few predictive markers that have been identified so far 
are insufficient, and there is a need in the clinic for more sophisticated characterization methods for 
AML. 
Drs. George Laszlo and Roland Walter in the Clinical Research Division recently published results 
from discovery gene expression studies utilizing pediatric AML specimens. They found an 
association between patient outcomes and the expression level of MMRN1, which is a gene that 
encodes the protein multimerin-1, a member of the elastin microfibrillar interface protein 
(EMILIN)/multimerin family. To follow up on their findings, the Fred Hutch investigators initiated a 
retrospective study in which MMRN1 expression was quantified in frozen samples of bone marrow 
from patients enrolled in two Children's Oncology Group AML protocols. The data were then 
correlated with clinical outcomes to assess the potential use of MMRN1 as a predictive biomarker in 
childhood AML. 
The results were recently accepted for publication in Clinical Cancer Research, showing large 
variation in MMRN1 expression among AML patients. The researchers arbitrarily divided the patients 
into quartiles, making the cut point dividing the highest quartile from the lower three quartiles at a 
relative MMRN1 expression of 0.5. In the first part of the study 183 specimens were compared, 
showing that patients with a relative expression of ≥ 0.5 (n = 45) fared worse than those with a 
relative expression of < 0.5 (n = 138). While there was no statistically significant difference in overall 
survival (OS) in this training cohort, patients withMMRN1 ≥ 0.5 experienced shorter event-free 
survival (EFS; time from study entry to failed initial remission, relapse, or death), and higher relapse 
risk (RR). 
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Next, MMRN1 expression levels were correlated with clinical outcomes and disease characteristics 
in 740 patients, using the established threshold. In this cohort, a significant trend indicated higher 
likelihood for standard- or high-risk disease characteristics among patients with a high 
relative MMRN1 expression (≥ 0.5; n = 160); the same population experienced lower probability of 
low-risk disease. In addition, these patients were less likely to respond to initial chemotherapy, and 
had poorer long-term outcome in terms of OS, EFS, and RR. After adjusting for disease risk, age, 
bone marrow blast percentage, and treatment, it was demonstrated that MMRN1 expression could 
indeed be used for prediction of aforementioned clinical endpoints in childhood AML. Subgroup 
analyses to assess the predictive potential in low-, standard-, and high-risk groups were limited by 
the relatively small sample size, but indicated that patients with high MMRN1 expression in all three 
risk categories generally fared worse than those with lower relative expression. 
The mechanisms behind the observed correlation have yet to be fully revealed, as MMRN1 is 
previously unrecognized as a predictive biomarker for any human cancer. In fact, it "comes totally 
out of nowhere in terms of myeloid biology," according to Dr. Laszlo. "We stumbled upon MMRN1 as 
a gene that co-segregates with a proteasomal degradation complex component, called SOCS2, 
which also happens to have high transcript level in poor prognosis patients, but whereas there is 
rationale for SOCS2 expression being aberrantly high in some bad-acting pediatric AMLs, there is 
very little known about MMRN1 biology that would indicate what role it might have in leukemic cells." 
Besides expanding the analyses to include adult AML, the Walter Lab is thus interested in digging 
into the biology behind their findings to explore whether there is a biological basis for high 
multimerin-1 levels in myeloid cells and whether secreted multimerin-1 could serve as an AML 
biomarker. 
Further studies are needed to assertively conclude whether MMRN1 expression can refine the risk 
stratification and improve current predictive models for AML, but this unexpected finding may bring 
the scientists one step closer to advancing the development of individualized treatment plans - a 
sought-after goal. 
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang Y-C, Ries R, Raimondi SC, 
Hirsch BA, Gamis AS, Meshinchi S, Walter RB. 2015. Multimerin-1 (MMRN1) as novel adverse 
marker in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Clin 
Cancer Res. [Epub ahead of print] 
 
May 18, 2015 SCIENCE SPOTLIGHT 
 
3 Volume 5, Issue 5 | Fred Hutchinson Cancer Research Center 
 
 
See also: Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, 
Hirsch BA, Gamis AS, Meshinchi S, Walter RB. 2014. High expression of suppressor of cytokine 
signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's 
Oncology Group. Leuk Lymphoma. 55(12):2817-21. 
 
 
 
Image provided by Dr. George Laszlo 
Clinical outcome in patients with high (relative mRNA expression ≥ 
0.5) and low (relative mRNA expression < 0.5) MMRN1 expression 
in COG-AAML0531. 
 
